Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Guo, Cai ping ^a   Liu, Ke wei ^a   Luo, Hai bo ^a   Chen, Hong bo ^a   Zheng, Yi ^a   Sun, Shen nan ^a   Zhang, Qian ^a   Huang, Laiqiang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN E; CYCLIN E1; LUCIFERASE; PEPTIDE PEP 7; PROTEIN E7; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; PEPTIDE; PEPTIDE LIBRARY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN STABILITY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; VIRUS CELL INTERACTION; WESTERN BLOTTING; ANIMAL; CELL CLONE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; ENDOCYTOSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PAPILLOMA VIRUS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CLONE CELLS; E2F TRANSCRIPTION FACTORS; ENDOCYTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PEPTIDE LIBRARY; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STABILITY; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952678427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017734     Document Type: Article

References (57)

1. Schiffman MH, Brinton LA, (1995) The epidemiology of cervical carcinogenesis. Cancer 76: 1888-1901.
2. Durst M, Gissmann L, Ikenberg H, zur Hausen H, (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 80: 3812-3815.
3. Steele C, Shillitoe EJ, (1991) Viruses and oral cancer. Crit Rev Oral Biol Med 2: 153-175.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
5. Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R, (2008) HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 375: 611-623.
6. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, et al. (2000) Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121: 216-225.
7. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, et al. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8: 3676-3685.
8. Veldman T, Horikawa I, Barrett JC, Schlegel R, (2001) Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 75: 4467-4472.
9. Nishimura A, Nakahara T, Ueno T, Sasaki K, Yoshida S, et al. (2006) Requirement of E7 oncoprotein for viability of HeLa cells. Microbes Infect 8: 984-993.
10. Dyson N, Howley PM, Munger K, Harlow E, (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937.
11. Boyer SN, Wazer DE, Band V, (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56: 4620-4624.
12. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K, (2001) Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75: 7583-7591.
13. Gammoh N, Grm HS, Massimi P, Banks L, (2006) Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol 80: 1787-1797.
14. Zhang B, Chen W, Roman A, (2006) The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci U S A 103: 437-442.
15. Caldeira S, Dong W, Tommasino M, (2005) Analysis of E7/Rb associations. Methods Mol Med 119: 363-379.
16. Wu EW, Clemens KE, Heck DV, Munger K, (1993) The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J Virol 67: 2402-2407.
17. Avvakumov N, Torchia J, Mymryk JS, (2003) Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 22: 3833-3841.
18. Huang SM, McCance DJ, (2002) Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 76: 8710-8721.
19. DeMasi J, Huh KW, Nakatani Y, Munger K, Howley PM, (2005) Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding. Proc Natl Acad Sci U S A 102: 11486-11491.
20. Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, et al. (2005) Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A 102: 11492-11497.
21. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, et al. (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451-11460.
22. Shillitoe EJ, Kamath P, Chen Z, (1994) Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther 1: 193-204.
23. Nauenburg S, Zwerschke W, Jansen-Durr P, (2001) Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J 15: 592-594.
24. Stanley M, (2003) Chapter 17: Genital human papillomavirus infections-current and prospective therapies. J Natl Cancer Inst Monogr pp. 117-124.
25. Sima N, Wang S, Wang W, Kong D, Xu Q, et al. (2007) Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 106: 299-304.
26. Knapp AA, McManus PM, Bockstall K, Moroianu J, (2009) Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology 383: 60-68.
27. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, et al. (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3: 1079-1085.
28. Rose PG, Blessing JA, Gershenson DM, McGehee R, (1999) Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Journal of Clinical Oncology 17: 2676-2680.
29. Burnett AF, Roman LD, Garcia AA, Muderspach LI, Brader KR, et al. (2000) A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 76: 63-66.
30. Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, et al. (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A gynecologic oncology group study. Journal of Clinical Oncology 23: 4626-4633.
31. Lowy DR, Schiller JT, (2006) Prophylactic human papillomavirus vaccines. J Clin Invest 116: 1167-1173.
32. Agosti JM, Goldie SJ, (2007) Introducing HPV vaccine in developing countries-key challenges and issues. N Engl J Med 356: 1908-1910.
33. Parkin DM, Bray F, (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24 (Suppl 3): S3/11-25.
34. Banks L, Edmonds C, Vousden KH, (1990) Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 5: 1383-1389.
35. Banks L, Barnett SC, Crook T, (1990) HPV-16 E7 functions at the G1 to S phase transition in the cell cycle. Oncogene 5: 833-837.
36. Helt AM, Galloway DA, (2001) Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol 75: 6737-6747.
37. Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, et al. (2007) Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 81: 9737-9747.
38. Wang J, Sampath A, Raychaudhuri P, Bagchi S, (2001) Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 20: 4740-4749.
39. Berezutskaya E, Yu B, Morozov A, Raychaudhuri P, Bagchi S, (1997) Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ 8: 1277-1286.
40. Ikeda MA, Jakoi L, Nevins JR, (1996) A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci U S A 93: 3215-3220.
41. Moberg K, Starz MA, Lees JA, (1996) E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 16: 1436-1449.
42. Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, et al. (1995) E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci U S A 92: 2403-2407.
43. Liu X, Clements A, Zhao K, Marmorstein R, (2006) Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 281: 578-586.
44. Helt AM, Galloway DA, (2001) Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. Journal of Virology 75: 6737-6747.
45. Clemens KE, Brent R, Gyuris J, Munger K, (1995) Dimerization of the human papillomavirus E7 oncoprotein in vivo. Virology 214: 289-293.
46. Ohtani K, DeGregori J, Nevins JR, (1995) Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 92: 12146-12150.
47. Henglein B, Chenivesse X, Wang J, Eick D, Brechot C, (1994) Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci U S A 91: 5490-5494.
48. XJ XZS (2009) Fast and Almost 100% Efficiency Site-directed Mutagenesis by The Megaprimer PCR Method. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS 36: 6.
49. Dona MG, Giorgi C, Accardi L, (2007) Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis. BMC Cancer 7: 25.
50. Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, et al. (2003) Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 9: 5028-5035.
51. Tom R, Bisson L, Durocher Y, (2008) Transfection of Adherent HEK293-EBNA1 Cells in a Six-Well Plate with Branched PEI for Production of Recombinant Proteins. Cold Spring Harbor Protocols.
52. De Falco G, Bellan C, Lazzi S, Claudio P, La Sala D, et al. (2003) Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene 22: 6214-6219.
53. Nie CL, Gao GL, Han J, Li H, Chen HP, et al. (2008) Human Papillomavirus 16 E6, E7 siRNAs Inhibit Proliferation and Induce Apoptosis of SiHa Cervical Cancer Cells. Chinese Journal of Cancer Research 20: 301-306.
54. Williams JPST, Li B, Mulloy R, Dimova D, Classon M, (2006) The retinoblastoma protein is required for Ras-induced oncogenic transformation. Mol Cell Biol 26: 13.
55. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL, (2005) Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 202: 1599-1611.
56. Jares P, Campo E, Pinyol M, Bosch F, Miquel R, et al. (1996) Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol 148: 1591-1600.
57. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Takahira T, et al. (2008) Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol 134: 1097-1103.